EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nicotinic Treatment for Cognitive Dysfunction

E D Levin, A H Rezvani

Current Drug Target -CNS & Neurological Disorders · 2002

DOI: 10.2174/1568007023339102 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Drug Target -CNS & Neurological Disorders, 2002. Verfasst von E D Levin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA. edlevin@duke.edu. Die Arbeit wurde bisher 152-mal zitiert (Crossref). Gefördert von: NIDA NIH HHS, NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nicotinic medications may provide beneficial therapeutic treatment for cognitive dysfunction such as Alzheimer's disease, schizophrenia and attention deficit hyperactivity disorder (ADHD). For development of nicotinic treatments we are fortunate to have a well characterized lead compound, nicotine. Transdermal nicotine patches offer a way to deliver measured doses of nicotine in a considerably safer fashion than the more traditional means of administration, tobacco smoking. We have found that transdermal nicotine significantly improves attentional function in people with Alzheimer's disease, schizophrenia or ADHD as well as normal nonsmoking adults. To follow-up on this proof of principal that nicotinic treatment of cognitive dysfunction holds promise, it is important to use animal models to determine the critical neurobehavioral bases for nicotinic involvement in cognitive function so that more selective nicotinic analogues that improve cognitive function with fewer side effects can be developed. We have found with local infusion in rat studies that the hippocampus and amygdala are important substrates for nicotinic effects on working memory function. Both alpha7 and alpha4beta2 nicotinic receptors are involved in working memory. Nicotinic interactions with dopaminergic and glutaminergic systems are also important in the basis of cognitive function. Studies of the neural nicotinic mechanisms underlying cognitive function are key for opening avenues for development of safe and effective nicotinic treatments for cognitive dysfunction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAnimalsAttention Deficit Disorder with HyperactivityCognition DisordersHumansNicotinic AgonistsNicotinic AntagonistsSchizophrenia

Substanzen

Nicotinic AgonistsNicotinic Antagonists

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA. edlevin@duke.edu

Förderung

  • NIDA NIH HHS
  • NIMH NIH HHS

Zitieren

APA

Levin, E. D., & Rezvani, A. H. (2002). Nicotinic Treatment for Cognitive Dysfunction. Current Drug Target -CNS & Neurological Disorders. https://doi.org/10.2174/1568007023339102

Vancouver

Levin ED, Rezvani AH. Nicotinic Treatment for Cognitive Dysfunction. Current Drug Target -CNS & Neurological Disorders. 2002. doi:10.2174/1568007023339102

BibTeX
@article{Levin2002,
  author = {Levin, E D and Rezvani, A H},
  title = {Nicotinic Treatment for Cognitive Dysfunction},
  journal = {Current Drug Target -CNS & Neurological Disorders},
  year = {2002},
  doi = {10.2174/1568007023339102}
}
Kostenlos starten →